Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

A Chinese pharmaceutical company expects to hire up to 500 employees for the first phase of its new campus in northern ...

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

Like many industries preparing for Donald Trump's second term as president, the prospects for the healthcare industry are a ...

As recently as five years ago, China was a bit player in biotechnology as their percentage of worldwide clinical trial ...

Aragen, based in Hyderabad, says it will use the funds to boost manufacturing capacity for newer treatment modalities, such ...

Innophore will launch the CavitOmiX AI tool to screen for new drugs, predict side effects, and repurpose existing molecules.

The Indian pharmaceutical market sees negative volume growth in Q3FY25 but benefits from strong pricing and new product ...